U.S. Stem Cell, Inc. (USRM)

Market Cap	662.00
Revenue (ttm)	82.05K
Net Income (ttm)	-2.86M
Shares Out	661.51M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0000 - 0.0003
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About U.S. Stem Cell

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company’s lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells or cells from a patient’s body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-der...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 11
• Stock Exchange: OTCMKTS
• Ticker Symbol: USRM

Financial Performance

In 2022, U.S. Stem Cell's revenue was $82,049, a decrease of -59.13% compared to the previous year's $200,749. Losses were -$2.86 million, -13.06% less than in 2021.